Transthyretin Amyloid Cardiomyopathy Clinical Trial

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Summary

The purpose of this study is to:

Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
Characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting
Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

Current enrollment in a clinical trial for any investigational agent

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

1500

Study ID:

NCT04561518

Recruitment Status:

Recruiting

Sponsor:

Alnylam Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Clinical Trial Site
La Jolla California, 92037, United States
Clinical Trial Site
Los Angeles California, 90095, United States
Clinical Trial Site
Jacksonville Florida, 32224, United States
Clinical Trial Site
Iowa City Iowa, 52242, United States
Clinical Trial Site
Kansas City Kansas, 66160, United States
Clinical Trial Site
Baltimore Maryland, 21224, United States
Clinical Trial Site
Boston Massachusetts, 02127, United States
Clinical Trial Site
New York New York, 10034, United States
Clinical Trial Site
Durham North Carolina, 27710, United States
Clinical Trial Site
Columbus Ohio, 43210, United States
Clinical Trial Site
Philadelphia Pennsylvania, 19104, United States
Clinical Trial Site
Austin Texas, 78756, United States
Clinical Trial Site
Houston Texas, 77030, United States
Clinical Trial Site
Salvador , , Brazil
Clinical Trial Site
Arhus , , Denmark
Clinical Trial Site
Copenhagen , , Denmark
Clinical Trial Site
Bordeaux , , France
Clinical Trial Site
Bron , , France
Clinical Trial Site
Le Kremlin-Bicêtre , , France
Clinical Trial Site
Marseille , , France
Clinical Trial Site
Berlin , , Germany
Clinical Trial Site
Hanover , , Germany
Clinical Trial Site
Jerusalem , , Israel
Clinical Trial Site
Ramat Gan , , Israel
Clinical Trial Site
Milan , , Italy
Clinical Trial Site
Naples , , Italy
Clinical Trial Site
Palermo , , Italy
Clinical Trial Site
Roma , , Italy
Clinical Trial Site
Groningen , , Netherlands
Clinical Trial Site
Lisbon , , Portugal
Clinical Trial Site
Porto , , Portugal
Clinical Trial Site
Barcelona , , Spain
Clinical Trial Site
Madrid , , Spain
Clinical Trial Site
Palma , , Spain
Clinical Trial Site
New Taipei City , , Taiwan
Clinical Trial Site
Taipei , , Taiwan

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

1500

Study ID:

NCT04561518

Recruitment Status:

Recruiting

Sponsor:


Alnylam Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.